We investigated specific antibody responses against two Plasmodium vivax vaccine candidates, PvMSP-119 and PvMSP-3α359−798. Moreover, we assessed the relationship between these antibodies and morbidity parameters.
In this study, a set of five monoclonal antibodies against recombinant HRPII (rHRPII) were generated and assessed for their potential in diagnostics.
We designed a polyvalent hybrid recombinant protein incorporating sequences of the three major allelic types of block 2 together with a composite repeat sequence of one of the types and N-terminal flanking T cell epitopes, and compared this with a series of recombinant proteins containing modular sub-components and similarly expressed in Escherichia coli.
This study highlights an important step achieved toward development of a protective vaccine against placental malaria.
Our results indicates that PvMSP3 is highly immunogenic in naturally exposed populations, where 78% of studied individuals present IgG immune response against the full-length recombinant protein (PVMSP3-FL) and IgG subclass profile was similar to all five recombinant proteins studied with a high predominance of IgG1 and IgG3.
A highly sensitive radioimmunoassay for detection of P. falciparum antibodies and antigens is described.
Abundant circulating MPs are present during acute P. vivax infection, and platelet derived-MPs may play a role on the acute inflammatory symptoms of malaria vivax.
Levels of IgG antibody to pregnancy‐specific VSAs decrease during receipt of IPTp. Antibody levels in early pregnancy did not predict clinical outcome. IPTp and decreasing malaria prevalence pose challenges for the evaluation of novel interventions for malaria during pregnancy.
These data highlight the importance of rational vaccine design and support the advancement of adenovector delivery technology for a malaria vaccine.
This review gives an overview of the erythrocyte invasion process, which has been described to include several different antigens.